Reviewer’s report

Title: Efficacy and safety of tenofovir in a kidney transplant patient with chronic hepatitis B and nucleos(t)ide multidrug resistance: a case report

Version: 3 Date: 5 April 2014

Reviewer: Evangelos Cholongitas

Which of the following best describes what type of case report this is?: Presentations, diagnoses and/or management of new and emerging diseases

Has the case been reported coherently?: Yes

Is the case report authentic?: Yes

Is the case report ethical?: No

Is there any missing information that you think must be added before publication?: Yes

Is this case worth reporting?: Yes

Is the case report persuasive?: Yes

Does the case report have explanatory value?: Yes

Does the case report have diagnostic value?: Yes

Will the case report make a difference to clinical practice?: Yes

Is the anonymity of the patient protected?: Yes

Comments to authors:

This is an interesting and well written case report regarding the use of tenofovir plus entecavir in kidney transplant recipient with multidrug resistance HBV infection.

There are some issues which should be addressed by the authors

1) The patient had glomerulonephritis before transplantation. This was related with HBV infection?

2) It is so clear when the diagnosis of HBV infection was performed, before or after transplantation. For example: “Monotherapy with lamivudine 100 mg daily was started at the month 1” What is month 1?
3) A comment in the discussion that Telbivudine is not a good option in LAM resistance

4) Which method was used for GFR calculation?

5) Page 5: “we adjusted adefovir dose”. But this was given 10mg/day.

6) The table is not a good option to present the course. May a diagram be better?

7) Emphasize that nucleoside+tenofovir is better option compared to nucleoside+adefovir providing that tenofovir is available

**Quality of written English:** Needs some language corrections before being published

**Declaration of competing interests:**

none